Psychiatry

A new study identifies antipsychotics to avoid for patients with schizophrenia who have cognitive deficits, including haloperidol, fluphenazine, and clozapine.

Factors, including older age at onset and longer length of stay, may predict longevity for schizophrenia in psychiatric long-term care settings.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.

Xanomeline trospium chloride offers a new pathway in schizophrenia treatment, improving cognitive symptoms without D2 receptor-related side effects like tardive dyskinesia.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

HCPLive spoke with Monroe regarding muscarinic modulators, both the ones in development and xanomeline trospium chloride capsules (Cobenfy).

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.

In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.

In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

A study links conversion therapy with worse mental health, such as PTSD and depression, showing a need for legislative action and support for LGBTQ+ individuals.

This Month in Review features the approval of trospium chloride capsules (Cobenfy) as well as other clinical trials in the psychiatry field.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.